Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80
Organisation › Details

Vaximm AG

VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor. The Company has a pipeline of complementary development candidates targeting different tumor structures. Lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including brain cancer. VAXIMM also has a neoantigen program (VXM NEO) currently in preclinical development; the Company’s platform allows for fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by other neoantigen approaches. VAXIMM has a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs. VAXIMM’s investors include: BB Biotech Ventures, BioMed Partners, CMS, M Ventures and Sunstone Capital. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities. *

 

Period Start 2011-01-15 existent
  Group Vaximm (Group)
  Predecessor Merck KGaA
Products Industry therapeutic vaccine
  Industry 2 VXM01 cancer vaccince
     
Region Region Basel BS
  Country Switzerland
  Street 3 Elisabethenstr.
  City 4051 Basel BS
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Vaximm AG. (11/12/19). "Press Release: NEC and Vaximm Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines". Tokyo, Basel & Mannheim.
     
   
Record changed: 2019-12-03

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Vaximm (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80




» top